Phaseline

Companies › OHB Neonatology

OHB Neonatology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mecasermin Rinfabate (OHB-607)
Insulin-like growth factor I receptor agonist
IGF1RPhase 2Bronchopulmonary DysplasiaJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03253263Mecasermin Rinfabate (OHB-607)Phase 2Bronchopulmonary DysplasiaCardiovascularJan 2028

Targets

IGF1R (1)

Companies with the same targets

Innovent Biologics (Suzhou) Amgen Candid Therapeutics Viridian Therapeutics Minghui Pharmaceutical (Hangzhou) Sling Therapeutics Zai Lab (Shanghai)

Companies built like this

Merakris Therapeutics Arch Biopartners Tectonic Operating Company CuraSen Therapeutics Neurimmune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.